$1.22
+0.08 (+7.02%)
Open$1.17
Previous Close$1.14
Day High$1.22
Day Low$1.11
52W High$2.85
52W Low$1.78
Volume—
Avg Volume299.0K
Market Cap86.26M
P/E Ratio—
EPS$-1.86
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+131.1% upside
Current
$1.22
$1.22
Target
$2.82
$2.82
$1.78
$2.82 avg
$3.37
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 19.42M | 19.36M | 17.02M |
| Net Income | -2,266,322 | -2,263,432 | -1,770,857 |
| Profit Margin | -11.7% | -11.7% | -10.4% |
| EBITDA | -3,805,934 | -3,485,255 | -2,994,447 |
| Free Cash Flow | -1,809,844 | -1,626,073 | -1,604,802 |
| Rev Growth | +9.6% | -8.7% | +9.0% |
| Debt/Equity | 1.27 | 1.74 | 1.38 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |